192 related articles for article (PubMed ID: 26482577)
1. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy.
Adams HJA; Nievelstein RAJ; Kwee TC
Ann Hematol; 2016 Jan; 95(1):1-9. PubMed ID: 26482577
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
[TBL] [Abstract][Full Text] [Related]
6. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Eur J Radiol; 2016 Nov; 85(11):1963-1970. PubMed ID: 27776647
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?
Adams HJ; Kwee TC; de Keizer B; Fijnheer R; de Klerk JM; Littooij AS; Nievelstein RA
Ann Oncol; 2014 May; 25(5):921-7. PubMed ID: 24351400
[TBL] [Abstract][Full Text] [Related]
8. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.
Castagna L; Bramanti S; Balzarotti M; Sarina B; Todisco E; Anastasia A; Magagnoli M; Mazza R; Nozza A; Giordano L; Rodari M; Rinifilo E; Chiti A; Santoro A
Br J Haematol; 2009 May; 145(3):369-72. PubMed ID: 19344403
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
13. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
14. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
[TBL] [Abstract][Full Text] [Related]
17. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E
Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382
[TBL] [Abstract][Full Text] [Related]
18. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
20. Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis.
Adams HJA; Kwee TC
Crit Rev Oncol Hematol; 2019 Sep; 141():73-81. PubMed ID: 31252322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
